Latest News
-
Best-corrected visual acuity (BCVA) changes and ocular symptoms may affect the management of belantamab mafodotin (belamaf) dosing among patients with relapsed or refractory multiple myeloma (RRMM), according to research presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Investigators conducted a post hoc investigation from the DREAMM-2 trial (ClinicalTrials.gov... -
Roughly 1 out of 15,000 people born suffer from Facioscapulohumeral Muscular Dystrophy (FSHD), a rare disease that starts with the progressive weakening of facial muscles and then the shoulders and upper body. By the time patients reach their 50s, around one-fifth of them are wheelchair bound. Now, a team of... -
Creating a strategy to discontinue eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) is reasonable and safe and improves quality of life, according to research in Blood. The strategy should be based on complement genetics. Eculizumab has drastically improved outcomes for patients with aHUS. There’s no clearly defined optimal duration...
Videos
Rare disease spotlight
We are honored to be recognized for our work in helping the #raredisease community during the COVID-19 pandemic.
Read the article here: https://www.bizjournals.com/boston/news/2021/06/29/meeting-needs-in-rare-disease-takes-more.html
For more resources about COVID-19 and rare diseases, please visit: https://globalgenes.org/coronavirus-covid-19-resources/